

## (19) AUSTRALIAN PATENT OFFICE

(54) Title	Controlled release dosage forms		
(51) <sup>6</sup> International Patent Classification(s)	A61J 3/06 (2006.01) 20060101ALI2005122 <b>A61K</b> 9/20 (2006.01) OBMJP <b>A61K</b> <b>A61K</b> 9/22 (2006.01) 9/52 <b>A61K</b> 9/28 (2006.01) 20060101ALI2006052 <b>A61K</b> 9/30 (2006.01) 1BMWO <b>A61K</b> <b>A61K</b> 9/32 (2006.01) 9/54 <b>A61K</b> 9/36 (2006.01) 20060101ALI2006052 <b>A61K</b> 9/48 (2006.01) 1BMWO <b>A61K</b> <b>A61K</b> 9/52 (2006.01) 9/56 <b>A61K</b> 9/54 (2006.01) 20060101ALI2006052 <b>A61K</b> 9/56 (2006.01) 1BMWO <b>A61K</b> <b>A61K</b> 9/62 (2006.01) 9/62 <b>A61K</b> 9/66 (2006.01) 20060101ALI2006052 <b>A61K</b> 31/135 1BMWO <b>A61K</b> (2006.01) 9/66 <b>A61K</b> 47/02 (2006.01) 20060101ALI2006052 <b>A61K</b> 47/12 (2006.01) 1BMWO <b>A61K</b> <b>A61K</b> 47/14 (2006.01) 31/135 <b>A61K</b> 47/20 (2006.01) 20060101ALI2005100 <b>A61K</b> 47/22 (2006.01) OBMJP <b>A61K</b> <b>A61K</b> 47/32 (2006.01) 47/02 <b>A61K</b> 47/34 (2006.01) 20060101ALI2005122 <b>A61K</b> 47/36 (2006.01) OBMJP <b>A61K</b> <b>A61K</b> 47/38 (2006.01) 47/12 <b>A61K</b> 47/44 (2006.01) 20060101ALI2005122 A61J 3/06 OBMJP <b>A61K</b> 20060101AFI2005122 47/14 OBMJP <b>A61K</b> 20060101ALI2005122 9/20 OBMJP <b>A61K</b> 20060101ALI2005122 47/20 OBMJP <b>A61K</b> 20060101ALI2005122 9/22 OBMJP <b>A61K</b> 20060101ALI2006052 47/32 1BMWO <b>A61K</b> 20060101ALI2005122 9/28 OBMJP <b>A61K</b> 20060101ALI2005100 47/34 8BMEP <b>A61K</b> 20060101ALI2005122 9/30 OBMJP <b>A61K</b> 20060101ALI2006052 47/36 1BMWO <b>A61K</b> 20060101ALI2005122 9/32 OBMJP <b>A61K</b> 20060101ALI2006052 47/38 1BMWO <b>A61K</b> 20060101ALI2005122 9/36 OBMJP <b>A61K</b> 20060101ALI2006052 47/44 1BMWO <b>A61K</b> 20060101ALI2005122 9/48 OBMJP PCT/US03/04867		
(21) Application No:	2003211146	(22) Application Date:	2003.02.21
(87) WIPO No:	W003/072089		
(30) Priority Data			
(31) Number	(32) Date	(33) Country	
60/357,851	2002.02.21	US	
(43) Publication Date :	2003.09.09		
(43) Publication Journal Date :	2003.10.16		

(71) Applicant(s)  
Biovail Laboratories International S.R.L.

(72) Inventor(s)  
Zhou, Fang, Maes, Paul J

(74) Agent/Attorney  
Davies Collison Cave, GPO Box 4387, Melbourne, VIC, 3001

(56) Related Art  
US 5204121  
US 5639476

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number  
WO 03/072089 A1

(51) International Patent Classification<sup>2</sup>: A61K 9/48, (74) Agents: CANTOR, Herbert, I. et al.; Crowell & Moring, 9/66, 9/52, 9/54, 9/56, 9/62, 9/20, 9/22, 9/28, 9/30, 9/36, I.L.P., P.O. Box 14300, Washington, DC 20044-4300 (US). 9/14, 9/16, 9/50

(21) International Application Number: PCT/US03/04867

(22) International Filing Date: 21 February 2003 (21.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/357,851 21 February 2002 (21.02.2002) US

(71) Applicant (for all designated States except US): BIOVAIR LABORATORIES INC. [BB/BB]; Chelston Park, Building 1, Ground Floor, Collymore Rock, St. Michael (BB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ZHOU, Fang [CA/US]; 13296-A Leafcrest Lane, #202, Fairfax, VA 22033 (US). MAES, Paul, J. [BE/US]; 10205 Windsor View Drive, Potomac, MD 20854 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, IR, IIR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, IN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/072089 A1

(54) Title: CONTROLLED RELEASE DOSAGE FORMS

(57) Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55°C and an aqueous dispersion of a neutral ester copolymer lacking functional groups.

**CONTROLLED RELEASE DOSAGE FORMS****RELATED APPLICATIONS**

**[0001]** This application claims priority from United States provisional patent application No. 60/357,851 filed February 21, 2002.

**FIELD OF THE INVENTION**

**[0002]** This invention relates to a novel monolithic film coating for obtaining controlled release of drugs from oral dosage forms.

**BACKGROUND**

**[0003]** The manner in which chemicals or drugs are administered has gained increasing attention in the past two decades. Normally, a chemical is administered in a high dose at a given time only to have to repeat that dose several hours or days later. This is not economical and sometimes results in damaging side effects. As a consequence, increasing attention has been focused on methods of giving drugs continually for prolonged time periods and in a controlled fashion. Controlled or sustained release dosage forms provide a therapeutic dose of the drug soon after administration, and then gradually release the drug over an extended period of time. The primary method of accomplishing this controlled release has been through incorporating the drugs within polymers or to surround or encapsulate a core comprising the drug with a polymer coat. Depending on the type and amount of drug, as well as the type and amount of polymer and other pharmaceutically acceptable excipients the desired controlled release profile can be obtained.

**[0004]** The majority of polymers used to develop coatings for controlled release dosage forms are hydrophobic and can be applied either dry, from a solution, or suspension. As most of these polymers are poorly soluble in water, they are usually applied by dissolving the polymer in an organic solvent and then sprayed onto the drug core and evaporating off the solvent. The use of organic solvents, however, is considered problematic for several reasons. The most

obvious reason relates to the safety hazards associated with the use of organic solvents. Organic solvents in general are highly flammable and carcinogenic. Further, organic solvents are expensive and the storage, disposal and use of organic solvents raise environmental concerns. Accordingly, it would be desirable to prepare aqueous suspensions or solutions of controlled release coatings comprising hydrophobic polymers suitable for coating a wide variety of drug cores.

**[0005]** Eudragit® NE30D, which contains 30% solids, is one of the first aqueous polymeric dispersions used for coating pharmaceutical dosage forms. Eudragit® NE30D has many advantages over other polymers for use as a film former for obtaining a controlled release drug profile and is thus ideally suited for controlled or sustained release drug formulations. The polymer forms a soft, flexible film at room temperature without any plasticizer. Also, no reactions or absorptive effects are observed when the polymer comes in direct contact with a therapeutically active agent. It is prepared by emulsion polymerization and consists of neutral copolymers of ethyl acrylate-methyl methacrylate esters that are insoluble over the entire physiological pH range but will still swell in water and give permeable membranes. The permeability is independent of pH and is thus suitable for the development of pH-independent modified-release oral dosage forms, provided that the solubility of the drug is also pH-independent.

**[0006]** One of the most significant differences between aqueous polymeric solutions and dispersions is the role water plays during film formation. In solutions, water is a solvent and drying is accompanied by an excessive increase in viscosity, which in turn suppresses the rate of evaporation. Excess energy is therefore required to drive off the water. In contrast, in polymeric dispersions such as Eudragit® NE30D, water is only a dispersion medium and does not solvate the polymers. Consequently, less heat is needed to evaporate the water. Fast water evaporation coupled with the high solids content of the dispersion significantly reduces processing time. These properties are especially critical when dealing with highly water-soluble or moisture sensitive therapeutically active agents.

**[0007]** The pigment binding capacity of Eudragit® NE30D is very high, so that up to ~2-3 parts by weight of additives can be incorporated into 1 part by weight of dry polymer without affecting the film properties. The polymer is also compatible with a wide variety of pharmaceutical excipients.

**[0008]** Plasticizers are generally added to coating formulations to modify the physical properties i.e., the glass transition temperature (Tg) of the polymer to make it more usable. The Tg is the temperature at which an amorphous polymer (or the amorphous regions in a partially crystalline polymer) changes from a hard and relatively brittle condition to a viscous or rubbery condition. Plasticizers function by decreasing the Tg of the polymer so that under ambient conditions the films are softer, more pliable and often stronger, and thus better able to resist mechanical stress. Eudragit® NE30D, however, has a low Tg and accordingly does not require the use of plasticizers. In fact, addition of plasticizers can be detrimental as it can increase the viscosity of the Eudragit® NE30D formulation and negate one of the distinct advantages of the dispersion over the polymeric solution. Incorporation of plasticizers into Eudragit® NE30D formulations can also increase the tackiness of the coat and complicate the coating process (Ghebre-Sellassie and Nesbit. *Application of Eudragit E30D in Controlled-Release Coatings in Aqueous Polymeric Coatings for Pharmaceutical Forms*, J. McGinity Ed., 1989, Marcel Dekker, Inc., pp 247-266).

**[0009]** Due to its low Tg, Eudragit® NE30D is sensitive to excessive drying conditions or exposure to high temperatures. Ghebre-Sellassie and Nesbit (*Application of Eudragit E30D in Controlled-Release Coatings in Aqueous Polymeric Coatings for Pharmaceutical Forms*, J. McGinity Ed., 1989, Marcel Dekker, Inc., pp 247-266) state that excessive drying of Eudragit® NE30D coats can be detrimental as such conditions do not allow the coating formulation to spread out evenly and promote particle deformation and coalescence. Also, during the coating process, the product temperature should be kept at around 26°C. If the product temperature is very high, the coating material becomes tacky owing to the low Tg of Eudragit® NE30D, which leads to agglomeration of the coated product. Ghebre-Sellassie and Nesbit also emphasize that Eudragit®

NE30D coated products should not be stored at temperatures above 40°C, as stability tests conducted at elevated temperatures may not correlate with the long-term behavior of Eudragit® NE30D coated products at room temperature.

**[0010]** Attempts have been made in the prior art to design microporous aqueous polymer coatings suitable for use on drug cores to obtain controlled or sustained release profiles using the Eudragits, and in particular Eudragit® NE30D. US Patent No. 5,529,791 for example, teaches controlled release dosage forms of Diltiazem in which the Diltiazem drug core is surrounded by a water-soluble and/or dispersible film forming polymer or copolymer constituting the microporous membrane. The polymers or copolymers taught include the polyacrylates and polymethacrylates of the Eudragit type, such as Eudragit NE30D, L30D, and RS30 D, ethylcelluloses, hydroxypropyl cellulose and hydroxypropylmethylcellulose and their derivatives. In addition to the polymer or copolymer, the microporous membrane contains, preferably, talc and/or magnesium stearate as a lubricant, polyvinylpyrrolidone as a plasticizer, titanium dioxide as a pigment, Tween 80 as an emulsifier, and silicone oil as an antifoaming agent. Other plasticizers taught include triacetin, dibutylphthalate, dibutylsebacate, citric acid esters, polyethyleneglycols, and polypropyleneglycols. The Eudragit® NE30D coated beads were cured for 16 hours at 50 °C (Example 3) or for 15 hours at 45 °C, 5-10 °C beyond the recommended temperature for Eudragit® NE30D. Further, long-term stabilization data was not presented for the coated products, and accordingly, it is not known what effect the elevated temperature had, if any, on the stability of the controlled release dosage form of Diltiazem.

**[0011]** US Patent No. 5,286,493 is directed to stabilized controlled release formulations having an aqueous acrylic polymer coating. The '493 patent also teaches the use of controlled release coatings covering a solid dosage form. The coating is derived from aqueous dispersions of an acrylic resin, which provides a substantially stable release pattern of a drug from the dosage form. The acrylic resins taught are the ammonio methacrylate co-polymers as for example Eudragit® RL30D, RS30D and combinations thereof. The acrylic coatings

include an effective amount of a suitable plasticizing agent. The stable Eudragit® RL30D and/or RS30D coated products are cured at temperatures above the Tg of the acrylic polymers. The '493 patent does not teach the use of Eudragit® NE30D.

**[0012]** US Patent No. 5,478,573 teaches delayed, sustained-release propranolol pharmaceutical preparations purportedly achieved by surrounding a water-soluble drug core with a hydratable diffusion barrier which delays drug release by for about 2-10 hours. The hydratable diffusion barrier is said to comprise a film-forming polymer such as acrylic resin or ethyl cellulose or mixtures thereof and an additive which controls the rate of hydration and permeability of the diffusion barrier. The preferred insoluble film-forming polymers are aqueous dispersions of fully esterified acrylic resins such as Eudragit® NE30D. The additives controlling the rate of hydration and permeability of the diffusion barrier are preferably selected from the group consisting of fully esterified acrylic resins containing quaternary amine side chains, anionic surfactants, lubricants, plasticizers, inert water soluble materials and mixtures thereof. The '573 patent teaches that the drug beads coated with the aqueous polymeric dispersion are dried at 35°C to 60°C for 8 hours to 5 days. No data is presented on the long-term stability of the products.

**[0013]** Another controlled release pharmaceutical dosage form using an aqueous acrylic polymer dispersion is taught in US Patent No. 5,871,776. The controlled release profile is obtained, however, using multiple layers of films. The outermost layer is comprised of the aqueous acrylic polymer dispersion. The preferred acrylic polymer is Eudragit® NE30D. The coatings may also contain other pharmaceutically acceptable excipients such as fillers, anti-adherents, pharmaceutically acceptable pigments and lubricants/glidants. The coated drug pellets are cured at a temperature in the range of from about 30°C to about 50°C, preferably from about 35°C to about 45°C and most preferably about 40°C for a period of about 5 to about 10 days, an preferably about 7 days. The inventors surprisingly found that in contrast to the preferred short curing times taught in the

prior art, long curing times help stabilize the release of the drug from the coated pellets after long storage periods.

5 [0014] International Patent Publication No. WO 02/058677 describes a film coating composition comprising an aqueous acrylic polymer dispersion, a surfactant, and sodium stearyl fumarate. The acrylic polymer dispersion is preferably Eudragit® NE30D. There does not appear to be any teaching as to the curing temperature and furthermore no data is presented with regard to long-term stability of the coated product.

10 [0015] In summary, it would seem that although the prior art teaches the use of aqueous acrylic dispersion coatings of Eudragit® NE30D, in most part, the prior art does not seem to have overcome long term stability problems of products coated with aqueous Eudragit® NE30D dispersions. Where the products have been found to be stable, the length of curing is very long and this is inefficient to the manufacturing process and also raises problems with storage 15 of scale-up product. Accordingly, and given the advantages and versatility of Eudragit® NE30D, it would be desirable that a stable controlled or sustained release coat be developed with short curing times to enhance process times.

#### SUMMARY OF THE INVENTION

20 [0016] This invention advantageously provides a novel monolithic stable controlled release coating for use in coating oral pharmaceutical dosage forms.

25 [0017] In one aspect, the coating comprises an aqueous dispersion of a neutral ester copolymer without any functional groups; a poly glycol having a melting point greater than 55°C, and one or more pharmaceutically acceptable excipients; wherein said coating composition is coated onto said oral pharmaceutical dosage forms and cured at a temperature at least equal to or greater than the melting point of the poly glycol.

30 [0018] In another aspect, the invention provides a controlled release dosage form comprising a core, wherein the core comprises an effective amount of at least one therapeutically active agent, and one or more first

pharmaceutically acceptable excipients, and a stable controlled release monolithic coating composition for coating said core, said coating comprising an aqueous dispersion of a neutral ester copolymer without any functional groups; a poly glycol having a melting point greater than 55°C, and one or more pharmaceutically acceptable excipients; wherein said coating composition is coated onto said oral pharmaceutical dosage forms and cured at a temperature at least equal to or greater than the melting point of the poly glycol.

**[0019]** In one embodiment, the neutral ester copolymer without any functional groups is selected from the group consisting of Eudragit® NE30D and Eudragit® NE40D. Preferably, the neutral ester copolymer without any functional groups is Eudragit® NE30D. The neutral ester copolymer without any functional groups is present in an amount from about 1% to about 35% by weight of the coating composition.

**[0020]** In one embodiment, the poly glycol is selected from the group consisting of polyethylene glycol 6000, polyethylene glycol 8000, polyethylene glycol 10000 and polyethylene glycol 20000. The poly glycol is present in an amount from about 0.1% to about 10% by weight of the coat composition.

Preferably, the poly glycol is polyethylene glycol 8000.

**[0021]** The addition of pharmaceutically acceptable excipients to the coating composition is contemplated and can include anti-tacking agents, emulsifying agents, hydrophilic agents, anti-foaming agents, flavourants, colorants, sweeteners and any combination thereof. The preferred ant-tacking agent is talc, the preferred hydrophilic agent is hydroxypropyl methylcellulose, the preferred anti-foaming agent is simethicone, the preferred emulsifying agent is polyoxyethylene sorbitan mono-oleate, and the preferred colorant is titanium dioxide.

#### DETAILED DESCRIPTION OF THE INVENTION

**[0022]** The present invention is directed to novel aqueous dispersions of neutral ester copolymers without any functional groups suitable for use as coatings for controlled or sustained release drug dosage forms. The coating

formulation is quite versatile in that it can be used to coat a variety of drug cores and can be easily manipulated to obtain the desired drug release profile. In another embodiment, the invention consists of a controlled release pharmaceutical composition, in one embodiment, a tablet, comprising at least one form of a 5 therapeutically active agent, wherein the pharmaceutical composition comprises a core and a stable controlled release coating of the invention. In another embodiment, the pharmaceutical dosage form is selected from the group consisting of tablets and capsules.

10

15

20

25

30

[0023] I. Cores

[0024] The core comprises an effective amount of a therapeutically active agent and at least one pharmaceutically acceptable excipient, in one embodiment a lubricant, a binder and/or filler, and optionally a glidants as well as other pharmaceutically acceptable excipients.

[0025] A wide variety of therapeutically active agents is contemplated. These include but are not limited to anti-tussives, anti-histamines, decongestants, alkaloids, mineral supplements, vitamins, antacids, ion exchange resins, anti-cholesterolemics, anti-lipid agents, anti-arrhythmics, anti-pyretics, analgesics, appetite suppressants, anti-depressants, expectorants, anti-anxiety agents, anti-ulcer agents, anti-inflammatory substances, coronary dilators, opioid agonists, cerebral dilators, peripheral vasodilators, anti-biotics, anti-virals, psycho-tropics, anti-manics, stimulants, gastrointestinal agents, sedatives, anti-diarrheal agents, anti-anginal drugs, vasodilators, anti-hypertensive drugs, vasoconstrictors, migraine treatments, anti-infectives, tranquilizers, anti-psychotics, anti-tumor drugs, anticoagulants, antithrombic drugs, hypnotics, anti-emetics, anti-nauseants, anti-convulsants, neuromuscular drugs, hyper- and hypoglycemic agents, thyroid and anti-thyroid agents, diuretics, anti-spasmodics, uterine relaxants, mineral and nutritional additives, anti-obesity drugs, anabolic drugs, erythropoietic drugs, anti-asthmatics, cough suppressants, mucolytics, H<sub>2</sub>-antagonists, anti-uricemic drugs. Mixtures are operable depending on the type of drugs. The skilled artisan will know, based on his technical knowledge, which drug combinations are acceptable. The therapeutically active agent(s) are present in an amount from about 5% to about 99% by weight of the cores. The

amount present is highly dependent on the agent(s), the desired controlled release profile, and the strength of the desired dosage form. Different forms of the therapeutically active agent are also contemplated. One form of the therapeutically active agent may be the individually optically active enantiomers of the therapeutically active agent. Pharmaceutically acceptable salts, as for example pharmaceutically acceptable addition salts, of the therapeutically active agent(s) are also suitable. Suitable pharmaceutically acceptable addition salts may be the hydrochloride salt, the hydrobromide salt, the hydroiodide salt, the saccharinate salt etc.

**[0026]** Glidants improve the flowability of the excipient powder by reducing intraparticulate friction. This is especially important during tablet production at high production speeds and during direct compaction. Examples of glidants include but are not limited to starch, talc, lactose, stearates (such as for example magnesium stearate), dibasic calcium phosphate, magnesium carbonate, magnesium oxide, calcium silicate, Cabosil™, colloidal silica (Sylloid™) and silicon dioxide aerogels. Glidants, if present, range in amounts from greater than about 0% to about 20%, with amounts of about 0.1% to about 5% being typical.

**[0027]** Lubricants ensure that tablet formation and ejection can occur with low friction between the solid and the die wall. High friction during tabletting can cause a series of problems, including inadequate tablet quality (capping or even fragmentation of tablets during ejection, and vertical scratches on tablet edges) and may even stop production. Lubricants are thus included in almost all tablet formulations. Such lubricants include but are not limited to adipic acid, magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oils, sodium chloride, sterotex, polyoxyethylene, glyceryl monostearate, talc, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, sodium stearyl fumarate, light mineral oil and the like may be employed, with sodium stearyl fumarate being preferred. Waxy fatty acid esters, such as glyceryl behenate, sold as "Compritol™" products, can be used. Other useful commercial lubricants include "Stear-O-Wet™" and "Myvatex™ TL". Mixtures are operable. Lubricants are used in amounts typically ranging from greater than

about 0% to about 10%, with about 0.01% to about 5.0% by weight of the tablet preferred.

**[0028]** It is well known in the art that besides reducing friction, lubricants may cause undesirable changes in the properties of a tablet. The presence of a lubricant in the excipient powder is thought to interfere in a deleterious way with the bonding between the particles during compaction and thus reduce tablet strength. Because many lubricants are hydrophobic, tablet disintegration and dissolution are often retarded by the addition of a lubricant. Such negative effects are strongly related to the amount of lubricant present. Other considerations known in the art include the manner in which a lubricant is mixed, the total mixing time and the mixing intensity. In order to avoid these negative effects, hydrophilic substances may be substituted for the hydrophobic lubricants. Examples include, but are not limited to, surface-active agents and polyethylene glycol. A combination of hydrophilic and hydrophobic substances can also be used.

**[0029]** Anti-adherents reduce adhesion between the excipient powder mixture and the punch faces and thus prevent particles sticking to the punches, a phenomenon known in the art as "sticking" or "picking", and is affected by the moisture content of the powder. One example of antiadherent is microcrystalline cellulose. Many lubricants such as magnesium stearate have also antiadherent properties. However, other substances with limited ability to reduce friction can also act as antiadherents. Such substances include for example talc and starch. Mixtures are operable. Antiadherents, if present, range from about 0% to about 20% by weight of the tablet depending on the antiadherent being used.

**[0030]** Sorbents are substances that are capable of sorbing some quantities of fluids in an apparently dry state. Thus, oils or oil-drug solutions can be incorporated into a powder mixture, which is granulated and compacted into tablets. Other examples of sorbing substances include microcrystalline cellulose and silica.

**[0031]** Diluents or fillers are added to increase the bulk weight of the blend resulting in a practical size for compression. The ideal diluent or filler should fulfill

a series of requirements, such as: be chemically inert, be non-hygroscopic, be biocompatible, possess good biopharmaceutical properties (e.g. water soluble or hydrophilic), good technical properties (such as compactibility and dilution capacity), have an acceptable taste and be cheap. As a single substance cannot fulfill all these requirements, different substances have gained use as diluents or fillers in tablets.

**[0032]** Lactose is a common filler in tablets. It possesses a series of good filler properties, e.g. dissolves readily in water, has a pleasant taste, is non-hygroscopic and fairly non-reactive and shows good compactibility. Other sugars or sugar alcohols, such as glucose, sucrose, sorbitol and mannitol, have been used as alternative fillers to lactose, primarily in lozenges or chewable tablets because of their pleasant taste. Mannitol has a negative heat of solution and imparts a cooling sensation when sucked or chewed.

**[0033]** Apart from sugars, perhaps the most widely used fillers are celluloses in powder forms of different types. Celluloses are biocompatible, chemically inert, and have good tablet forming and disintegrating properties. They are therefore used also as dry binders and disintegrants in tablets. They are compatible with many drugs but, owing to their hygroscopicity, may be incompatible with drugs prone to hydrolyse in the solid state. The most common type of cellulose powder used in tablet formulation is microcrystalline cellulose.

**[0034]** Another important example of a diluent or filler is dibasic and tribasic calcium phosphate, which is insoluble in water and non-hygroscopic but is hydrophilic, i.e. easily wetted by water. Other examples of diluents include but are not limited to di- and tri-basic starch, calcium carbonate, calcium sulfate, and modified starches. Many diluents are marketed in "direct compression" form, which adds other desirable properties, such as flow and binding. There are no typical ranges used for the diluents, as targeted dose and size of a tablet are variables that influence the amount of diluent that should be used.

**[0035]** Binders (also sometimes called adhesives) are added to ensure that tablets can be formed with the required mechanical strength. Binders can be added in different ways: (1) As a dry powder, which is mixed with other

ingredients before wet agglomeration; (2) As a solution, which is used as agglomeration liquid during wet agglomeration. Such binders are often referred to as "solution binders", and (3) As a dry powder, which is mixed with the other ingredients before compaction (slugging or tabletting). Such binders are often referred to as "dry binders". Common traditional solution binders are starch, sucrose, and gelatin. More commonly used binders with improved adhesive properties, are polymers such as polyvinylpyrrolidone and cellulose derivates such as for example hydropropyl methylcellulose. Examples of dry binders include microcrystalline cellulose and crosslinked polyvinylpyrrolidone. Other examples of binders include but are not limited to pregelatinized starches, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone and polyvinylalcohols. Binders, if present, range in amounts from about greater than about 0% to about 25% depending on the binder used.

**[0036]** The manufacturing process of the core can be as follows. The at least one therapeutically active agent is first granulated with the at least one binder, in one embodiment a granulator, but not necessarily a fluidized bed granulator. The at least one binder is first dissolved or dispersed in a suitable solvent, in one embodiment water. The solution or suspension of the at least one binder is then sprayed onto the at least one therapeutically active agent in a granulator, in one embodiment a fluidized bed granulator. For example, fluidized bed granulators manufactured by Glatt (Germany) or Aeromatic (Switzerland) can be used for this operation. An alternative process can be to use a conventional or high shear mixer for granulation. If necessary, the at least one therapeutically active agent can be mixed with a filler, prior to the granulation step. Granules once dried can be mixed with the other pharmaceutically acceptable excipients, especially with the at least one lubricant, but also with at least one glidant and any other pharmaceutically acceptable excipient suitable to improve processing. The mixture of granules (in one embodiment with the at least one lubricant), and optionally at least one glidant is pressed into tablets. Alternatively, the at least one therapeutically active agent and the at least one

lubricant can be mixed in a granulator, in one embodiment a fluidized bed granulator, and heated to the melting point of the at least one lubricant to form granules. This mixture can then be mixed with at least one suitable filler and compressed into tablets. Also, it is possible to mix the at least one therapeutically active agent and the at least one lubricant (in one embodiment polyvinyl alcohol) in a granulator, in one embodiment a fluidized bed granulator, and then to press the resulting granules into tablets. Tablets can be obtained by standard techniques, in one embodiment on a (rotary) press (for example Manesty Betapress®) fitted with suitable punches. The resulting tablets are hereinafter referred as tablet cores.

[0037] The tablet cores are then coated with the semi-permeable coating designed to achieve a controlled release of the at least one therapeutically active agent.

[0038] II. Coating Formulation

[0039] Particularly useful neutral ester copolymers without any functional groups constituting the coat of the invention described herein are Eudragit® NE30D, Eudragit® NE40D (Röhm America LLC). The preferred polymer is Eudragit NE30D and is present in an amount of from about 1% to about 35% by weight of the coat depending on the therapeutically active agent used and the

controlled release profile desired. Preferably, the neutral ester copolymer without any functional groups is present in an amount from about 1% to about 35% by weight of the coating composition, more preferably from about 1% to about 25% by weight of the coating composition and more preferably in an amount from about

- 5 1% to 7% by weight of the coating composition. Hydrophilic agents may also be included in the coat to promote wetting of the coat when in contact with gastrointestinal fluids. Such hydrophilic agents include hydrophilic water soluble polymers such as hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC) and combinations thereof. HPMC is the preferred hydrophilic water soluble
- 10 polymer. If hydrophilic agents are to be included in the coat composition the agents should be present in an amount from about 0.1% to about 10% by weight of the coating composition, preferably from about 0.1% to about 6% by weight of the coating composition and most preferably from about 0.1% to about 3% by weight of the coating composition.
- 15 **[0040]** The coat formulation also comprises a poly glycol with a melting point of greater than 55°C. The poly glycol is selected from the group consisting of polyethylene glycol 6000, polyethylene glycol 8000, polyethylene glycol 10000, and polyethylene glycol 20000. The preferred poly glycol is polyethylene glycol 8000. Other suitable poly glycol derivatives having a melting point at least of 55°C
- 20 can be, but are not limited to, Poloxamer 188, Poloxamer 338, Poloxamer 407, Polyethylene Oxides, Polyoxyethylene Alkyl Ethers, Polyoxyethylene Stearates and Polyoxyethylene Sorbitan Fatty Acid Esters. Preferably, the polyethylene glycol or derivative thereof is present in an amount from about 0.1% to about 10% by weight of the coat composition, more preferably from about 0.1% to about 5%
- 25 by weight of the coat composition, more preferably from about 0.1% to about 3% by weight of the coat composition and more preferably from about 0.1% to about 0.5% by weight of the coat composition.

30

- 13A -

[0041] In addition to the copolymers and the poly glycol, the coating formulation comprises other pharmaceutically acceptable excipients. The excipients can include but are not limited to anti-tacking agents, emulsifying agents, antifoaming agents, flavourants, colourants, etc. It is known in the art that

5 depending on the intended main function, excipients can affect the properties of the coat in a series of ways, and many substances used in coat formulations can thus be described as multifunctional. A skilled worker will know, based on his technical knowledge, which pharmaceutically acceptable excipients are suitable for the desired controlled release coating composition.

10 [0042] The tackiness of polymeric films is important for the coating of solid dosage forms and for the subsequent curing step (post coating thermal treatment). During coating with either cellulosic or acrylic polymers, an unwanted, and sometimes irreversible agglomeration of several granules or beads or, in the worst case, of the complete batch, can occur, especially at higher product

15 processing temperatures. Accordingly, the addition of anti-tacking agents to coating formulations is desirable. The anti-tacking agents which can be used include but are not limited to adipic acid, magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oils, sterotex, glyceryl monostearate, talc, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, and the like

20 may be employed. Talc is the preferred anti-tacking agent. Talc may also function as a wetting agent. Mixtures of the anti-tacking agents are operable. The amount of anti-tacking agent in the coating composition is preferably in the range from about 1% to about 15% by weight of the coating dispersion and more preferably from about 1% to about 7% by weight of the coating dispersion.

25

30

**[0043]** The anti-foaming agents, which may be included in the coating composition of the invention include silicon oil or simethicone, with simethicone being the preferred anti-foaming agent. The anti-foaming agent, if present, is present in an amount up to about 0.5% by weight of the coat composition and preferably from about 0.1% to about 0.4% by weight of the coating composition.

**[0044]** The inclusion of an emulsifying agent or agents (also called emulsifiers or emulgents) is necessary to facilitate actual emulsification during manufacture of the coat, and also to ensure emulsion stability during the shelf-life of the product. Emulsifying agents useful for the coat composition of the invention include, but are not limited to naturally occurring materials and their semi synthetic derivatives, such as the polysaccharides, as well as glycerol esters, cellulose ethers, sorbitan esters and polysorbates. Mixtures are operable. The preferred emulsifying agent is Polysorbate 80 (polyoxyethylene sorbitan monooleate)(Tween 80). The emulsifying agent or agents are present in an amount up to about 0.5% by weight of the coat composition and preferably from about 0.1% to about 0.3% by weight of the coat composition.

**[0045]** Any permitted colourants in a film coat formula are invariably water-insoluble colors (pigments). Pigments have certain advantages over water-soluble colors in that they tend to be more chemically stable towards light, provide better opacity and covering power, and optimize the impermeability of a given film to water vapor. Examples of suitable colorants include, but are not limited to iron oxide pigments, titanium dioxide, and aluminum Lakes. Mixtures are operable. The preferred pigment is titanium dioxide. The pigment or colorant is present in an amount of from about 0.1% to about 10% by weight of the coat composition, preferably from about 0.1% to about 5% by weight of the coat composition and most preferably from about 0.1% to about 2% by weight of the coat composition.

**[0046]** The coating may be applied onto a core comprising an effective amount of the therapeutically active agent by a process, which involves the atomization (spraying) of the coating solution or suspension onto a bed of the tablet cores. Some examples of equipment suitable for film coating include:

Accela Cota (Manesty Machines, Liverpool, UK), Hi-Coater (Freund Company, Japan), Driacoater (Driam Metallprodukt GmbH, Germany), HTF/150 (GS, Italy), and IDA (Dumoulin, France). Examples of units that function on a fluidized-bed principle include: Aeromatic (Fielder, Switzerland and UK) and Glatt AG (Switzerland). The preferred and most widely used apparatus is the Accela Cota.

**[0047]** The coating fluid is delivered to the coating apparatus from a peristaltic pump at the desired rate and sprayed onto the rotating or fluidizing tablet cores. The tablet cores are pre-warmed to about 30°C. During the coating process, the product temperature range is maintained between about 25°C and 35°C by adjusting the flow rate of the inlet and outlet air, temperature of the inlet air and spray rate. A single layer of coat is applied and once spraying is complete, the coated tablet cores are dried between about 30°C to about 40°C for about 3-5 minutes at a low pan speed and low air flow. The pan was readjusted to jog speed, and drying continued for 12-15 minutes.

**[0048]** The coated tablet cores are placed onto a tray and cured (post coating thermal treatment) in an electrical or steam oven at a temperature above the temperature of the melting point of the polyethylene glycol or derivative thereof. The curing temperature is preferably greater than the melting point of the polyethylene glycol or derivative thereof. The curing time is preferably about 2 to about 7 hours. The cured coated tablets are subsequently cooled to room temperature.

**[0049]** The findings disclosed herein are particularly surprising in light of the prior art teachings with regard to Eudragit® NE30D. As mentioned above, Eudragit® NE30D has a low Tg and the use of plasticizers, such as polyethylene glycol or its derivatives, is not recommended. In fact, as mentioned above, the prior art teaches that the addition of plasticizers can be detrimental to Eudragit® NE30D. Surprisingly, however, applicants have found that addition of polyethylene glycol or its derivatives in the amounts described herein and curing the coated tablets at above the melting temperature of the polyethylene glycol provided for a controlled release of the therapeutically active agent. Moreover, the coated tablet cores were found to be stable over time. The desired

dissolution profile obtained provides a controllable lag time such as in an S-shaped Weibull profile. This is a surprising result and is not taught in the prior art. The controlled lag time and the desired dissolution profile can be accomplished by a single coating.

**[0050]** As will be seen from the non-limiting examples described below, the coating of the invention is quite versatile. The length and time for the delay is controlled by rate of hydration and the thickness of the coat. The drug release rate subsequent to the delay is determined by the thickness and permeability of the hydrated coat. Thus, it is possible to regulate the rate of hydration and permeability of the coat so that the desired controlled-release drug profile can be achieved. There is no preferred coat thickness, as this will depend on the drug being used in the core and also the controlled release profile desired. Other parameters in combination with the thickness of the coat include varying the concentrations of some of the ingredients of the stable coat composition of the invention described and/or varying the curing temperature and length of curing the coated tablet cores. The skilled artisan will know which parameters or combination of parameters to change for a desired controlled release profile.

**[0051]** The following non-limiting examples illustrate the invention:

#### EXAMPLE 1 METFORMIN HCL TABLETS

**[0052]** 1.1 TABLET CORE PREPARATION

**[0053]** The following formulation was prepared for Metformin HCl 500 mg strength tablets:

Ingredients	% w/w
Metformin HCl	95.70
Silicon Dioxide*	0.50
Polyvinyl alcohol (PVA)**	1.80
Atomized Glyceryl Behenate***	2.00
Total	100.00

\* Aerosil 200.

\*\* The PVA is prepared as a 4% solution (w/w) in purified water. The purified water is not

considered as part of the theoretical batch size since it is evaporated during drying of the core in the fluid bed granulator.

\*\*\* Compritol 888 ATO

**[0054]** All of the metformin and silicon dioxide was transferred to a V-blender and blended for about 10 min. The blended material was then discharged into a fluid bed granulator and granulation was carried out in the presence of the PVA solution under the following process parameters:

Granulation Temperature (°C)	35-45
Air Volume (m/s)	0.5-3.0
Atomization Air Pressure (Bar)	0.5-2.0
Fluid Spray Rate (g/min)	3-11
Drying Temperature (°C)	45-55

The LOD% of the granules after drying was NMT 3% as determined by moisture balance.

**[0055]** After drying, the granules were sized by passing the granules through a 0.71 mm screen. The screened granules were then transferred to a V-blender and blended with the remainder of the lactose and all of the atomized glyceryl behenate for about 10 min. Finally, the magnesium stearate was added and blending was carried out for about 5-10 more minutes.

**[0056]** The dissolution profile of the compressed tablet cores was determined under the following conditions:

Medium: 900 ml water

Method: USP Type II Apparatus, 50 rpm at 37°C.

**[0057]** The tablet cores are immediate release. The release of metformin HCl from the tablet cores was found to be about 100% in about 30 min.

**[0058]** 1.2 CORE COATING

**[0059]** The following three coating formulations were prepared:

Ingredients	Coating MA (%)	Coating MB (%)	Coating MC (%)
Eudragit NE30D	25.33	26.97	27.03
Talc 400	6.84	5.30	5.32
HPMC 606	5.98	2.47	2.25
PEG 8000	2.14	2.25	2.25
Titanium dioxide	1.71	1.35	1.35
Somethicone	0.39	0.31	0.31
Tween 80	0.34	0.23	0.23
Purified Water	57.27	61.12	61.26
<b>Total</b>	<b>100.00</b>	<b>100.00</b>	<b>100.00</b>

**[0060]** The metformin tablet cores were then coated with either one of the coating formulations. The coating process was carried out in a Glatt GPCG-1 apparatus equipped with a coating chamber without a Wuster column. The mesh size of the bottom screen was 200µm and the size of the spray nozzle was 1 mm.

**[0061]** The coating formulation was prepared as follows:

	Materials
<b>Component A</b>	Eudragit NE30D
	Water
<b>Component B</b>	HPMC 606
	Water
<b>Component C</b>	Simethicone (DOW CORNING®)
	Water
<b>Component D</b>	Tween 80
	Water

Component E	Component D+C
Component F	Talc
	PEG 8000 (MT)
	Titanium dioxide
	Water
<b>Final coating Dispersion G</b> (A +B+C+D+E+F)	

[0062] 1.2.1 Preparation of Component A

[0063] Water is transferred to a stainless steel container of a Silverson high-shear mixer and the mixer turned on at continuous low speed to produce a sufficient mixer. All of the assigned water is added to Eudragit NE 30D dispersion and mixed for about 10 min using a Caframo Mixer.

[0064] 1.2.2 Preparation of Component B

[0065] All of the Pharmacoat 606 is added to 65± 5 °C water and mixed for about 5 min using a silverson high shear mixer at a low speed.

[0066] 1.2.3 Preparation of Component C

[0067] All of the simethicone is placed in a 100 ml beaker to which 50g of water is added and mixed to uniformity.

[0068] 1.2.4 Preparation of Component D

[0069] All of the Tween 80 is transferred to a 100 ml beaker to which 50g of water is added and mixed until all the Tween 80 is dissolved.

[0070] 1.2.5 Preparation of Component E

[0071] Dispersion E is prepared by uniformly mixing component D and component C.

[0072] 1.2.6 Preparation of Component F

[0073] Water is transferred to a stainless steel container of a Silverson high-shear mixer and the mixer turned on at continuous low speed to produce a sufficient vortex. The PEG is added gradually to the vortex and mixed until the all of the PEG is dissolved. Components B and E are next added and mixing is

continued for 5 min. All of the talc and titanium dioxide is added and mixed for another 15 min.

**[0074]** 1.2.7 Preparation Final Coating Dispersion G

**[0075]** Component F is slowly added component A while stirring.

**[0076]** The processing parameters for coating the tablet cores were as follows:

Coating Temperature (°C)	30-32
Air Volume (m/s)	4.0-6.5
Atomization Air Pressure (Bar)	1.3-2.3
Coating Fluid Spray Rate (g/min)	3-6
Drying Temperature (°C)**	30-35

\*\* Coated tablets were dried for about 3 min.

**[0077]** After application of the coating the tablets were cured in an oven at  $62 \pm 2^{\circ}\text{C}$  for about 2 hours. This temperature is above the melting temperature of the polyethylene glycol 8000.

**[0078]** The metformin tablet cores were next coated with either one of the coating formulations MA, MB, or MC to a weight gain of either 14% or 16% w/w by weight of the tablet core and cured in an oven at between about  $60^{\circ}\text{C}$  to about  $75^{\circ}\text{C}$  for between about 2 hours to about 15 hours.

**[0079]** Dissolution tests of the coated tablet cores was carried out under the following dissolution conditions:

Medium: 900 ml water.

Method: USP Type II Apparatus, 50 rpm at  $37^{\circ}\text{C}$ .

**[0080]** The results are presented in Table 1 as a % release into the medium of the total metformin HCl in the tablet:

TABLE 1			
Time (h)	Tablet cores coated with coating formulation MA to 16% weight gain	Tablet cores coated with coating formulation MB to 14% weight gain	Tablet cores coated with coating formulation MC to 14% weight gain
0	0	0	0
1	21.15	11.26	7.04
2	50.35	24.4	16.59

3	73.8	38.12	26.69
4	89.73	52.75	38.02
5	98.65	66.73	50.56
6	102.24	79.25	63.31
7	103.55	88.78	74.98
8	-	95.41	84.71
9	-	99.42	91.92
10	-	101.76	96.47
11	-	103.05	99.45
12	-	103.86	101.21

**[0081]** A study was done to determine the effect of curing temperature and length of curing on drug dissolution. The curing temperature was set at 65°C for 1, 2 and 5 hours. The effect on the dissolution of the drug at a curing temperature of 75°C for about 2 hours was also determined. Dissolution tests of the coated tablets under the different curing temperatures and lengths of time were carried under the following dissolution conditions:

Medium: 900 ml water.

Method: USP Type II Apparatus, 50 rpm at 37°C.

**[0082]** The results are presented in Table 2 as a % release into the medium of the total metformin HCl in the tablet:

Time (h)	TABLE 2			
	MB (65°C-60 min)	MB (65°C -120 min)	MB (65°C -300 min)	MB (75°C -120 min)
0	0	0	0	0
1	9.98	8.08	7	6.47
2	23.73	18.65	17.14	15.76
3	40.53	29.8	27.62	25.67
4	61.77	42.52	39.8	36.6
5	81.77	56.48	53.84	48.63
6	92.51	71.32	67.67	60.74
7	-	80.94	79.85	72.57
8	-	86.35	88.24	82.13
9	-	90.36	92.96	88.28
10	-	92.69	95.47	91.68

11	-	94.87	97.57	94.02
12	-	96.14	98.39	95.67
13	-	97.37	99.23	96.93
14	-	98.21	99.69	97.56
15	-	98.71	99.97	98.33
16	-	99.47	100.37	98.83

**[0083]** A study was done to determine the effect of curing temperature and time on drug dissolution. The curing temperature was set at 55°C for 5 and 16 hours. The effect on the dissolution of the drug at a curing temperature of 70°C for about 2 hours was also determined. Dissolution tests of the coated tablets under the different curing temperatures and lengths of time were carried under the following dissolution conditions:

Medium: 900 ml water.

Method: USP Type II Apparatus, 50 rpm at 37°C.

**[0084]** The results are presented in Table 3 as a % release into the medium of the total metformin HCl in the tablet:

TABLE 3				
Time (h)	Tablet Cores	MC (55°C -5 hr)	MC (55°C -16 hr)	MC (70°C -2 hr)
0	0	0	0	0
1	103.92	13.08	11.86	7.04
2	-	37.54	32.76	16.59
3	-	54.51	54.39	26.69
4	-	67.48	67.85	38.02
5	-	78.38	78.89	50.56
6	-	87.14	88.15	63.31
7	-	93.31	93.43	74.98
8	-	96.5	96.12	84.71
9	-	98.11	97.55	91.92
10	-	99.11	98.36	96.47
11	-	99.51	98.82	99.45
12	-	99.91	99.13	101.21

**[0085]** The influence of the coat on different dissolution media relative to water was determined as follows:

Media: water, 0.1N HCl (pH1.2) + Citramide, or pH5.8 phosphate buffer + Citramide.

Method: USP Type II Apparatus, 50 rpm at 37°C.

**[0086]** The results are presented in Table 4 as a % release into the medium of the total metformin HCl in the tablet:

Time (h)	MC	MB	MC	MC	MB	MB
	water	water	pH 5.8+Citramide	pH 1.2+Citramide	pH 5.8+Citramide	pH 1.2+Citramide
0	0	0	0	0	0	0
1	7.04	11.26	5.62	5.74	8.61	8.98
2	16.59	24.4	13.28	13.39	19.69	20.58
3	26.69	38.12	20.99	20.83	31.23	31.96
4	38.02	52.75	29.47	28.94	43.42	43.46
5	50.56	66.73	38.99	37.84	56.09	54.97
6	63.31	79.25	49.47	47.76	68.35	66.08
7	74.98	88.78	60.68	58.06	78.89	76.22
8	84.71	95.41	72.25	68.75	86.79	84.81
9	91.92	99.42	81.02	77.34	92.06	89.75
10	96.47	101.76	86.63	83.99	95.01	92.56
11	99.45	103.05	90.01	87.32	96.72	94.64
12	101.21	103.86	92.45	90.03	97.77	95.52
13	102.36	104.25	94.27	92.21	98.49	96.58
14	103.38		95.51	93.2	98.97	96.79
15	104.06		96.61	94.45	99.34	97.45
16	104.77		97.46	95.47	99.6	97.74

**[0087]** The stability of the tablet coated with formulation MD coated to 16% weight gain stored at 40°C/75% relative humidity (RH) was determined at periodic intervals over a 10 month period by determining the dissolution of the metformin under the following conditions:

Media: 900 ml water

Method: USP Type II Apparatus, 50 rpm at 37°C.

[0088] The dissolution data is presented in Table 5 as a % release into the medium of the total metformin HCl in the tablet:

Time (h)	TABLE 5					
	0 Month	1 Month	2 Month	3 Month	6 Month	10 Month
1	7	5.3	7.3	8.3	3.3	9.7
2	16.6	13.8	16.9	19.1	13.4	21.4
4	38	35	39.7	46.8	38	49.7
8	84.7	79	87.3	98.1	89.4	92.9
12	101.2	90.4	99.4	106.8	102.8	99.9

[0089] A comparative study was conducted to determine the bioavailability following administration of a single dose metformin tablet (Tables 6 and 7) or multiple-dose metformin tablet (Table 8) of the invention

Time (Hrs)	Metformin HCl 500 mg ER Tablets, q.d. (Lot # 00F167)		Metformin HCl 500 mg ER Tablets, q.d. (Lot #07(C)/00 500 XL-HT)		Glucophage 500 mg, b.i.d. (Lot # C8J247A)	
	Mean	SD	Mean	SD	Mean	SD
0	0.00 ± 0.00		12.68 ± 39.85		2.51 ± 9.71	
2	7.37 ± 15.46		53.96 ± 31.93		73.39 ± 59.00	
4	343.92 ± 146.45		164.46 ± 65.57		200.20 ± 114.59	
5	476.22 ± 151.89		176.46 ± 80.87		485.69 ± 188.37	
6	390.96 ± 129.93		146.23 ± 65.48		630.49 ± 161.58	
7	325.99 ± 104.84		116.62 ± 59.84		707.85 ± 215.67	
8	284.59 ± 104.39		97.20 ± 51.97		651.46 ± 183.34	
9	242.05 ± 95.88		85.26 ± 47.76		466.04 ± 128.06	
10	204.51 ± 86.24		77.24 ± 43.17		259.19 ± 78.14	
12	127.37 ± 62.84		49.53 ± 28.71		158.77 ± 42.42	
16	60.11 ± 37.32		21.02 ± 19.97		55.69 ± 16.58	
20	40.52 ± 30.87		15.63 ± 16.54		25.93 ± 19.96	
24	19.64 ± 23.26		9.49 ± 14.00		6.01 ± 12.75	

SUBJECT	Metformin HCl 500 mg ER Tablets, q.d. (Lot # 00F167)			Metformin HCl 500 mg ER Tablets, q.d. (Lot #07(C)/00 500 XL-HT)			Glucophage 500 mg, b.i.d. (Lot # C8J247A)		
	C <sub>max</sub>	AUC <sub>0-t</sub>	T <sub>max</sub>	C <sub>max</sub>	AUC <sub>0-t</sub>	T <sub>max</sub>	C <sub>max</sub>	AUC <sub>0-t</sub>	T <sub>max</sub>
1	423.94	3203.04	5.0	296.51	1589.86	5.0	901.58	5608.64	3.0
2	357.51	4267.79	10.0	.	.	.	.	.	.
3	318.39	1602.89	5.0	216.55	1842.90	5.0	447.61	2971.16	5.0
4	489.60	2784.57	4.0	127.03	1447.85	4.0	510.26	3504.43	4.0
5	592.40	3864.41	5.0	166.35	1484.23	5.0	735.54	5394.77	4.0

6	414.96	2295.36	5.0	175.21	1285.79	5.0	686.09	4258.03	4.0
7	419.53	3619.34	5.0	191.15	1415.17	5.0	520.19	3435.10	3.0
8	227.86	1548.93	5.0	203.87	1373.32	4.0	806.18	5076.93	3.0
9	664.24	4366.66	5.0	187.89	1779.67	5.0	697.26	4994.51	2.0
10	583.18	3398.15	5.0	144.69	978.64	5.0	1002.36	6098.66	4.0
11	566.79	5048.15	6.0	173.95	1771.12	6.0	641.14	4709.57	5.0
12	573.18	3370.02	5.0	42.10	236.63	4.0	654.03	4208.54	4.0
13	302.20	2559.23	5.0	192.13	2090.60	5.0	586.54	4177.75	4.0
14	.	.	.	158.98	1152.05	4.0	1090.92	6671.03	5.0
16	625.70	4278.32	5.0	152.38	930.85	0.0	808.43	4882.53	4.0
19	640.76	3353.70	4.0	123.43	496.15	5.0	578.89	3108.53	2.0
20	768.94	4284.70	5.0	396.18	2689.22	5.0	1125.20	6308.03	4.0
Mean	498.1	3365.33	5.3	184.3	1410.25	4.5	737.0	4713.01	3.8
SD	151.9	1006.88	1.3	77.4	594.66	1.3	205.5	1133.00	0.9
CV (%)	30.5	29.92	25.6	42.0	42.17	29.3	27.9	24.04	24.8
GeoMean	474.1	3199.36	5.1	168.4	1247.38	4.8	711.4	4581.55	3.6
Min	227.86	1548.93	4.00	42.10	236.63	0.00	447.61	2971.16	2.00
Max	768.94	5048.15	10.00	396.18	2689.22	6.00	1125.20	6671.03	5.00

SUBJECT	Metformin HCl 500 mg ER Tablets, q.d. (Lot # 00F167)			Metformin HCl 500 mg ER Tablets, q.d. (Lot #07(C)/00 500 XL-HT)			Glucophage 500 mg, b.i.d. (Lot # C8J247A)		
	C <sub>max</sub>	AUC <sub>0-t</sub>	T <sub>max</sub>	C <sub>max</sub>	AUC <sub>0-t</sub>	T <sub>max</sub>	C <sub>max</sub>	AUC <sub>0-t</sub>	T <sub>max</sub>
1	945.40	6232.57	5.0	872.61	5177.02	5.0	886.47	12899.68	3.0
3	722.90	8312.65	5.0	475.83	4403.99	5.0	628.12	10229.16	15.0
4	540.79	4332.49	4.0	155.28	1538.15	4.0	580.82	7692.77	3.0
5	1562.92	10130.87	5.0	401.35	3980.27	5.0	988.26	12011.86	3.0
6	770.21	5346.66	6.0	425.47	3514.28	4.0	821.17	10603.35	3.0
7	560.34	4490.96	5.0	409.97	3884.59	5.0	721.95	10518.02	4.0
8	1105.38	8133.56	5.0	442.39	4111.28	5.0	757.45	11971.60	4.0
9	727.04	4863.71	5.0	541.01	5228.69	5.0	977.96	12244.88	4.0
10	1150.00	7974.91	5.0	694.61	4673.33	5.0	1123.79	14656.81	4.0
11	983.35	6791.08	5.0	594.71	5228.49	6.0	817.43	10463.89	5.0
12	961.04	6548.23	5.0	454.24	4037.80	5.0	856.27	11769.61	4.0
13	963.88	8612.93	6.0	430.68	4788.57	5.0	734.24	12074.02	4.0
14	.	.	.	615.73	5939.67	5.0	.	.	.
16	990.87	5890.99	5.0	359.87	3273.11	5.0	567.54	7890.22	3.0
19	835.28	4797.61	4.0	368.31	2801.78	4.0	893.94	11735.13	4.0
20	3835.55	11037.19	6.0	774.96	6522.10	5.0	970.78	15109.04	6.0
Mean	1110.3	6899.77	5.1	501.1	4318.94	4.9	820.4	11456.00	4.6
SD	795.1	2072.53	0.6	176.3	1222.75	0.5	158.5	2042.45	3.0
CV (%)	71.6	30.04	11.7	35.2	28.31	10.3	19.3	17.83	65.1
GeoMean	973.3	6620.63	5.0	469.2	4119.36	4.8	805.7	11278.47	4.1
Min	540.79	4332.49	4.00	155.28	1538.15	4.00	567.54	7692.77	3.00
Max	3835.55	11037.19	6.00	872.61	6522.10	6.00	1123.79	15109.04	15.00

## EXAMPLE 2 BUPROPION HCl TABLETS

## [0090] 2.1 TABLET CORE PREPARATION

**[0091]** The following formulation was prepared for Bupropion HCl 300 mg and 150 mg strength tablets:

Ingredients	% w/w
Bupropion HCl	93.75
Polyvinyl alcohol (PVA)*	3.31
Atomized Glyceryl Behenate**	2.94
Total	100.00

\*\* The PVA is prepared as a 4.6% solution (w/w) in purified water. The purified water is not considered as part of the theoretical batch size since it is evaporated during drying of the core in the fluid bed granulator.

\*\*\* Compritol 888 ATO

**[0092]** The tablet cores were prepared as described above for oxycodone HCl. The granules were compressed into either 320 mg tablets (for 300 mg strength tablets) or 160 mg tablets (for 150 mg strength tablets). The dissolution profile of the compressed tablets was determined under the following conditions:

Medium: 900 ml water

Method: USP Type II Apparatus, 50 rpm at 37°C.

**[0093]** The release of bupropion HCl from the tablet cores was found to be about 100% in about 30 minutes.

#### **[0094] 2.2 CORE COATING**

**[0095]** The following four coating formulations were prepared for the bupropion HCl 300mg strength tablet cores:

Ingredients	BA (% w/w)	BB(% w/w)	BC (%w/w)	BD (%w/w)	BE (%w/w)
Eudragit NE 30D(Liquid)	26.82	26.82	26.82	26.82	26.82
Talc 400	4.83	4.02	3.62	4.43	4.02
Titanium Dioxide	0.81	0.81	0.81	0.81	0.81
HPMC	2.01	2.82	3.22	2.41	2.82
PEG 8000	2.01	2.01	2.01	2.01	2.01
Simethicone	0.2	0.2	0.2	0.2	0.2
Tween 80	0.1	0.1	0.1	0.1	0.1

Purified water	63.22	63.22	63.22	63.22	63.22
Total	100.00	100.00	100.00	100.00	100.00

**[0096]** The following two coating formulations were prepared for the bupropion HCl 150mg strength tablet cores:

Ingredients	BF (w/w%)	BG (%w/w)
Eudragit NE 30D(Liquid)	26.82	26.82
Talc 400	4.02	3.62
Titanium Dioxide	0.81	0.81
HPMC 606	2.82	3.22
PEG 8000	2.01	2.01
Somethicone	0.2	0.2
Tween 80	0.1	0.1
Purified water	63.22	63.22
Total	100.00	100.00

**[0097]** The bupropion HCl 300 mg core tablets were coated with either one of the coat formulations BA-BE to 15% weight gain as described for the metformin HCl core tablets. Coated tablet cores were cured at 62 ± 2°C. Dissolution tests of the coated tablet cores was carried out under the following dissolution conditions:

Medium: 900 ml 0.1N HCl or water

Method: USP Type I Apparatus, 75 rpm at 37°C.

**[0098]** The results are presented in Table 9 and 10 as a % release into 0.1N HCl and water respectively of the total bupropion HCl in the 300 mg tablet:

TABLE 9				
Time (h)	BB	BC	BD	BE
0	0	0	0	0
1	2.6	4.18	1.73	2.2
2	5.9	9.03	4.23	4.58
3	9	14.3	6.44	6.62
4	12	19.89	8.43	10.25
5	15.5	27.23	10.44	12.93

6	19.3	33.14	12.6	16.65
7	23.7	40.45	14.9	20.43
8	28.5	46.81	17.32	24.39
9	33.7	52.46	20.04	29.24
10	39.1	59.59	23	34.72
11	44.5	64.57	26.3	38.98
12	49.9	69.7	29.84	44.62
13	55	74.6	33.66	47.26
14	59.9	78.17	37.89	51.94
15	64.5	81.99	41.85	56.03
16	69	85.05	46.37	60.72
17		88.58	50.72	63.61
18		91.14	54.7	67.4
19		92.25	58.4	70.4
20		93.62	62.1	73.93
21		94.86	65.6	76.55
22		95.72	68.9	77.86
23		96.25	72.1	79.97
24		96.69	75.1	82.32

TABLE 10					
Time (h)	BA	BB	BC	BD	BE
0	0	0	0	0	0
1	1	1.97	4.62	1.6	2.4
2	2.5	4.65	8.73	3.6	5.1
3	3.8	7.3	12.7	5.3	7.3
4	4.8	9.93	17.09	6.8	9.3
5	5.8	12.73	21.96	8.2	11.4
6	6.7	16	27.37	9.6	13.5
7	7.6	19.3	33.18	11	15.8
8	8.5	22.5	39.22	12.5	18.3
9	9.4	26	45.16	14	21
10	10.3	29.1	50.78	15.7	23.9
11	11.2	33.2	56.13	17.5	27.15
12	12.3	36.7	61.09	19.5	30.52
13	13.4	40.7	65.72	21.7	34.11

14	14.6	44.5	69.95	24.2	37.89
15	15.8	47.8	73.76	26.8	41.58
16	17.2	51.5	77.15	29.8	45.27
17		54.9	80.1	33.3	48.91
18		58.6	82.65	37.1	52.59
19		61.7	84.75	40.7	56.06
20		64.7	86.51	45.6	59.35
21		68.2	87.97	50.1	62.5
22		71.4	89.15	53.8	65.67
23		74.3	90.12	57.3	68.49
24		77	90.96	60.4	71.1

[0099] The 150 mg tablet cores were coated with formulations BF and BG to 15% and 25% weight gain respectively and dissolution tests were performed on these tablets under the following conditions:

Media: 900 ml 0.1N HCl

Method: USP Type I Apparatus, 75 rpm at 37°C

[0100] The dissolution data is presented in Table 11 as a % release into the medium of the total bupropion HCl:

TABLE 11		
Time (h)	BG (25% weight gain)	BF (15% weight gain)
0	0	0
1	1.61	2.89
2	5.75	6.9
3	9.89	10.83
4	14.3	15.3
5	19.3	20.38
6	24.58	25.98
7	29.97	31.91
8	35.18	37.86
9	40.18	43.79
10	44.87	49.29
11	49.33	54.64

12	53.55	59.58
13	57.49	64.28
14	61.33	68.63
15	64.87	72.65
16	68.24	76.34
17	71.41	79.71
18	74.32	82.7
19	77.05	85.31
20	79.55	87.52
21	81.84	89.38
22	83.92	90.97
23	85.64	92.34
24	87.31	93.47

**[0101]** The stability of the tablet coated with formulation BG supplemented with 0.65% titanium dioxide and 0.12% synthetic iron oxide pigment. The tablet was coated to 20% weight gain stored at 40°C/75% relative humidity (RH) was determined at periodic intervals over a 3 month period by determining the dissolution of the bupropion under the following conditions:

Media: 900 ml 0.1N HCl

Method: USP Type I Apparatus, 75 rpm at 37°C.

**[0102]** The dissolution data is presented in Table 12 as a % release into the medium of the total bupropion HCl in the tablet:

TABLE 12			
Time (h)	0 Month	1 Month	3 Month
2	6.0	6.2	6.4
4	14.4	15.3	15.7
8	36.6	41.0	42.1
16	72.8	82.6	84.2
24	92.3	99.4	93.6

**[0103]** A comparative study was conducted to determine the bioavailability following administration of a single dose bupropion tablet (Tables 13 and 14) the invention

TABLE 13

Time (Hrs)	Bupropion HCl 150 mg ER Tablets. (Lot # Bup-Bio (AQ) 02C-02/150-NE)	Bupropion HCl 150 mg ER Tablets. (Lot # Bup-Bio (AQ) 03A-02/150-S)	Bupropion HCl XL Tablets, 150 mg. (Lot # 02A063)
0	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
0.5	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
1	0.14 ± 0.51	0.00 ± 0.00	0.00 ± 0.00
1.5	1.37 ± 1.55	0.00 ± 0.00	0.00 ± 0.00
2	4.27 ± 2.25	0.00 ± 0.00	0.81 ± 1.64
2.5	7.14 ± 2.78	0.43 ± 0.60	3.25 ± 3.40
3	9.55 ± 3.57	1.15 ± 0.96	11.56 ± 10.81
3.5	11.49 ± 4.68	2.35 ± 1.72	22.75 ± 16.54
4	12.12 ± 4.91	3.26 ± 2.25	30.24 ± 18.87
4.5	13.35 ± 5.35	5.37 ± 4.20	39.88 ± 23.52
5	17.35 ± 6.80	7.27 ± 3.59	53.42 ± 20.15
5.5	17.40 ± 6.69	8.53 ± 3.34	60.76 ± 19.45
6	16.07 ± 5.48	9.40 ± 3.82	62.08 ± 18.83
8	13.00 ± 5.34	8.98 ± 4.17	46.47 ± 16.36
10	22.40 ± 10.48	16.39 ± 20.64	44.23 ± 15.86
12	34.46 ± 13.26	18.57 ± 13.43	35.14 ± 15.55
16	28.01 ± 9.36	27.36 ± 15.05	20.40 ± 6.96
24	17.87 ± 8.27	19.81 ± 8.32	10.11 ± 3.58
36	6.76 ± 3.93	8.51 ± 7.13	4.94 ± 1.58
48	3.51 ± 1.36	4.01 ± 2.26	3.41 ± 1.66
72	1.35 ± 0.88	1.65 ± 0.83	1.21 ± 0.90
96	0.19 ± 0.46	0.35 ± 0.55	0.21 ± 0.51
120	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00

SUBJECT	Bupropion HCl 150 mg ER Tablets. (Lot # Bup-Bio (AQ) 02C-02/150-NE)			Bupropion HCl 150 mg ER Tablets. (Lot # Bup-Bio (AQ) 03A-02/150-S)			Bupropion HCl XL Tablets, 150 mg. (Lot # 02A063)		
	AUC	C <sub>MAX</sub>	T <sub>MAX</sub>	AUC	C <sub>MAX</sub>	T <sub>MAX</sub>	AUC	C <sub>MAX</sub>	T <sub>MAX</sub>
1	783.88	27.72	24.0	637.03	36.23	12.0	654.49	74.73	5.5
2	366.41	28.05	12.0	550.51	30.78	16.0	534.11	53.70	6.0
3	1179.19	52.75	16.0	1223.27	86.66	10.0	1223.86	91.77	6.0
4	789.01	44.01	12.0	167.84	17.49	4.5	954.87	106.52	5.5
5	730.90	44.92	10.0	518.11	29.30	16.0	881.67	62.52	6.0
7	577.62	27.97	16.0	577.76	24.60	24.0	677.27	54.21	10.0
8	1095.68	32.75	24.0	1094.55	32.36	24.0	1098.80	75.11	10.0
9	494.33	23.05	12.0	496.00	17.49	16.0	440.79	43.58	5.5
10	1000.63	35.30	16.0	911.09	35.40	24.0	1093.05	70.28	5.5
12	837.22	32.33	12.0	877.09	23.13	36.0	747.36	50.07	5.0
13	855.14	46.38	12.0	911.36	58.44	16.0	836.02	69.49	6.0
14	806.11	55.63	12.0	572.52	21.93	16.0	1050.24	85.35	8.0
15	612.93	27.04	16.0	717.12	36.47	16.0	613.25	72.73	5.5
16	654.03	57.51	12.0	699.39	23.97	16.0	1082.74	71.07	6.0
Mean	770.22	38.24	14.71	710.90	33.87	17.61	849.18	70.08	6.46
Std. Dev.	224.61	11.70	4.41	272.38	18.43	7.55	243.23	17.02	1.65
CV (%)	29.16	30.58	29.97	38.32	54.41	42.85	28.64	24.29	25.47
GeoMean	737.74	36.63	14.20	650.74	30.60	16.00	814.20	68.19	6.30
Min	366.41	23.05	10.00	167.84	17.49	4.50	440.79	43.58	5.00
Max	1179.19	57.51	24.00	1223.27	86.66	36.00	1223.86	106.52	10.00

## EXAMPLE 3. TRAMADOL HCl TABLETS

## [0104] 3.1 TABLET CORE PREPARATION

[0105] The following formulation was prepared for tramadol HCl 40 mg or 80 mg strength tablets:

Ingredients	% w/w	%w/w
Tramadol HCl	40.0	80.0
Silicon Dioxide*	0.4	0.4
Polyvinyl alcohol (PVA)**	1.1	0.9
Lactose Anhydrous DT	56.5	16.69
Atomized Glyceryl Behenate***	2.00	2.00
Total	100.00	100.00

\* Aerosil 200.

\*\* The PVA is prepared as a 3.8% solution (w/w) in purified water. The purified water is not considered as part of the theoretical batch size since it is evaporated during drying of the core in the fluid bed granulator.

\*\*\* Compritol 888 ATO

[0106] All of the ingredients were transferred into a V-blender and processed as described above for metformin HCl. The granules were subsequently compressed into tablets.

[0107] The dissolution profile of the compressed tablet cores was determined under following conditions:

Medium: 900 ml water

Method: USP Type II Apparatus, 75 rpm at 37°C

[0108] The tablet cores are immediate release. The release of tramadol HCl from the tablet cores was found to be 100% in about 30 min.

### 3.2 CORE COATING

[0109] The following four coat formulations were prepared:

Ingredients	TA (%w/w)	TB (%w/w)	TC (%w/w)	TD (%w/w)
<b>Eudragit NE 30D(Liquid)</b>	38.5	33.3	27.74	28.82
<b>Talc 400</b>	4.7	4.21	4.14	4.32
<b>Titanium Dioxide</b>	1.6	1.35	1.2	1.24
<b>HPMC 606</b>	1.4	1.35	1.02	1.05
<b>PEG 8000</b>	0	1.18	0	0.43
<b>Simethicone</b>	0.32	0.25	0.2	0.21
<b>Tween 80</b>	0.24	0.2	0.12	0.12
<b>Purified water</b>	53.24	58.16	65.58	63.81
<b>Total</b>	100	100	100	100

[0110] The coating procedure was carried out as described above for metformin HCl tablet cores. Coated tablet cores were cured at 62 ± °C for about 2 hours.

[0111] The tramadol tablet cores were coated with either one of the coating formulations TA, TB, TC, and TD. The coating was applied to a weight gain of approximately 8% to about 18%. Curing temperatures ranged from about 60°C to about 65°C and curing times were for either 3 or 4 hours. Dissolution tests were carried out as follows:

Medium: 900ml 0.1N HCl (pH 1.2)

Method: USP Type I Apparatus, 75 rpm at 37°C.

[0112] The dissolution data is presented in Table 15 as a % release into the medium of the total tramadol HCl:

TABLE 15				
Time (h)	TD (8% weight gain, cured at 65°C for 3 hrs)	TC (8% weight gain, cured at 60°C for 3 hrs)	TB (13% weight gain, cured at 60°C for 4 hrs)	TA (18% weight gain, cured at 60°C for 3 hrs)
0	0	0	0	0
1	1.15	1.64	0.29	1.31
2	3.05	5.16	0.44	1.94
3	5.48	10.83	0.89	2.5
4	8.32	21.09	1.73	3.23
5	11.26	37.21	2.89	3.92
6	15.07	51.97	4.1	4.93
7	20	65.54	5.32	5.94
8	25.01	76.21	6.55	6.97
9	30.96	83.67	7.92	8.24
10	36.99	90.23	9.22	9.65
11	43.48	94.47	10.58	12.1
12	49.4	97.8	12.07	17.08
13	55.33	100.02	13.55	21.78
14	60.97	101.6	15.25	31.93
15	66.43	102.66	17.02	38.89
16	71.33	103.39	19.12	44.12
17	76.25	103.92	21.3	48.31
18	80.54	-	23.76	52.18
19	84.05	-	26.36	55.78
20	87.18	-	28.93	58.96
21	89.85	-	31.48	61.62
22	91.87	-	-	64.63
23	93.65	-	-	66.97
24	95.2	-	-	69.54

[0113] Tablets coated with formulation TC were cured at either 60°C for 3 hrs or for 22 hrs or at 70°C for 3 hrs. Dissolution tests were conducted as follows:

Media: 900 ml 0.1N HCl

Method: USP Type I Apparatus, 75 rpm at 37°C

**[0114]** The dissolution data is presented in Table 16 as a % release into the medium of the total tramadol HCl:

TABLE 16			
Time (h)	TC cured at 60°C for 22 hrs	TC cured at 70°C for 3 hrs.	TC cured at 60°C for 3 hrs
0	0	0	0
1	1.4032	1.3888	1.64
2	3.9566	3.8022	5.16
3	7.9378	7.3746	10.83
4	13.631	12.784	21.09
5	21.956	20.607	37.21
6	32.55	31.338	51.97
7	44.124	42.846	65.54
8	54.9	53.873	76.21
9	64.3	63.568	83.67
10	73	71.219	90.23
11	79.5	77.418	94.47
12	84	82.787	97.8
13	88.5	86.683	100.02
14	91.5	89.748	101.6
15	94	92.209	102.66
16	96	94.006	103.39
17	97.7	95.484	103.92
18	98.9	96.959	
19	100	97.853	
20	100.6	98.695	
21	101.4	99.294	
22	101.9		
23	102.4		
24	102.6		

**[0115]** The 80 mg tramadol tablet core was coated to about 8% weight gain with formulation TD and cured at about 65°C for about 3 hours. Dissolution tests on the tablets was conducted under the following conditions:

Media: 900 ml, 0.1N HCl, pH 5.8 phosphate buffer or pH 6.8 phosphate buffer.

Method: USP Type I Apparatus, 75 rpm at 37°C.

[0116] The dissolution data is presented in Table 17 as a % release into the medium of the total tramadol HCl:

Time (h)	TD-pH1.2	TD-pH5.8	TD-pH6.8
0	0	0	0
1	0.58	0.5	0.44
2	1.49	1.96	1.61
3	2.66	3.81	2.84
4	4.12	6.2	4.58
5	6.18	7.79	6.99
6	9.34	12.6	11.16
7	14.43	18.73	19.19
8	22.98	28.78	32.31
9	34.85	42.14	48.55
10	49.13	55.48	62.39
11	62.65	65.45	71.68
12	73.37	72.39	78.03
13	81.08	77.11	82.39
14	85.36	80.71	85.52
15	88.37	83.36	87.77
16	90.66	85.54	89.72
17	92.34	87.33	91.14
18	93.79	88.83	92.42
19	94.92	89.9	93.44
20	95.74	91.04	94.3
21	96.36	91.72	95.08
22	96.97	92.63	95.65
23	97.51	93.11	96.25
24	97.94	93.68	96.78

2003211146 04 Jul 2007

PROPERDATA2003211146 amendment.doc-27/6/2007

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or

5 group of integers or steps.

The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication

10 (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

15

20

25

30

- 37A -

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A stable controlled release monolithic coating composition for use in coating a pharmaceutical oral dosage form, said coating comprising:
  - 5 a) an aqueous dispersion of a neutral ester copolymer without any functional groups;
  - b) a poly glycol having a melting point greater than 55°C; and
  - c) one or more pharmaceutically acceptable excipients;wherein said coating composition is coated onto said pharmaceutical oral dosage form and cured at a temperature at least equal to or greater than the melting point of said poly glycol.
- 10 2. The stable controlled release coating composition of claim 1 wherein said neutral ester copolymer without any functional groups is selected from the group consisting of Eudragit NE30D, Eudragit NE40D and any combination thereof.
- 15 3. The stable controlled release coating composition of claim 2 wherein said neutral ester copolymer without any functional groups is NE30D.
- 20 4. The stable controlled release coating composition of any one of claims 1 to 3 wherein said neutral ester copolymer without any functional groups is present in an amount of from about 1% to about 35% by weight of the coating composition.
- 25 5. The stable controlled release coating composition of claim 4 wherein said neutral ester copolymer without any functional groups is present in an amount of from about 1% to about 25% by weight of the coating composition.
- 30 6. The stable controlled release coating composition of claim 5 wherein said neutral ester copolymer without any functional groups is present in an amount of from about 1% to about 7% by weight of the coating composition.
7. The stable controlled release coating composition of any one of claims 1

2003211146 04 Jul 2007

to 6 wherein said poly glycol is selected from the group consisting of polyethylene glycol 8000, polyethylene glycol 10000, polyethylene glycol 20000, Poloxamer 188, Poloxamer 338, Poloxamer 407, Polyethylene Oxides, Polyoxyethylene Alkyl Ethers, Polyoxyethylene Sorbitan Fatty Acid Esters, and Polyoxyethylene

5 Stearates.

8. The stable controlled release coating composition of any one of claims 1 to 7 wherein said poly glycol is selected from the group consisting of polyethylene glycol 8000, polyethylene glycol 10000, polyethylene glycol 20000 and any 10 combination thereof.

9. The stable controlled release coating composition of claim 8 wherein said polyethylene glycol is polyethylene glycol 8000.

15 10. The stable controlled release coating composition of any one of claims 1 to 9 wherein said polyethylene glycol or derivative thereof is present in an amount of from about 0.1% to about 10% by weight of the coat composition.

20 11. The stable controlled release coating composition of claim 10 wherein said polyethylene glycol or derivative thereof is present in an amount of from about 0.1% to about 5% by weight of the coat composition.

25 12. The controlled release coating composition of claim 11 wherein said polyethylene glycol or derivative thereof is present in an amount of from about 0.1% to about 3% by weight of the coat composition.

13. The controlled release coating composition of claim 12 wherein said polyethylene glycol or derivative thereof is present in an amount of from about 0.1% to about 0.5% by weight of the coat composition.

30

14. The stable controlled release coating composition of any one of claims 1 to 13 wherein the one or more pharmaceutically acceptable excipients is selected

from the group consisting of anti-tacking agents, emulsifying agents, hydrophilic agents, anti-foaming agents, flavourants, colourants, sweeteners and any combination thereof.

5 15. The stable controlled release coating composition of claim 14 wherein the anti-tacking agent is selected from the group consisting of adipic acid, magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oils, sterotex, glyceryl monostearate, talc, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate and any combination thereof.

10

16. The stable controlled release coating composition of claim 15 wherein the anti-tacking agent is talc.

17. The stable controlled release coating composition of any one of claims 14  
15 to 16 wherein the anti-tacking agent is present in an amount of from about 1% to about 15% by weight of the coating composition.

18. The stable controlled release coating composition of claim 16 wherein the anti-tacking agent is present in an amount of from about 1% to about 7% by weight  
20 of the coating composition.

19. The stable controlled release coating composition of any one of claims 14  
20 to 18 wherein said hydrophilic agent is selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose and any combination  
25 thereof.

20. The stable controlled release coating composition of claim 19 wherein said hydrophilic agent is hydroxypropyl methylcellulose.

30 21. The stable controlled release coating composition of any one of claims 14  
20 to 20 wherein said hydrophilic agent is present in an amount from about 0.1% to about 10% by weight of the coat composition.

22. The stable controlled release coating composition of claim 21 wherein said hydrophilic agent is present in an amount from about 0.1% to about 6% by weight of the coat composition.

5

23. The stable controlled release coating composition of claim 22 wherein said hydrophilic agent is present in an amount from about 0.1% to about 3% by weight of the coating composition.

10 24. The stable controlled release coating composition of any one of claims 14 to 23 wherein said anti-foaming agent is selected from the group consisting of silicon oil, simethicone and any combination thereof.

15 25. The stable controlled release coating composition of claim 24 wherein said anti-foaming agent is simethicone.

26. The stable controlled release coating composition of any one of claims 14 to 25 wherein said anti-foaming agent is present in an amount up to about 0.5% by weight of the coating composition.

20

27. The stable controlled release coating composition of claim 26 wherein said anti-foaming agent is present in an amount from about 0.1% to about 0.4% by weight of the coating composition.

25 28. The stable controlled release coating composition of any one of claims 14 to 27 wherein said emulsifying agent is selected from the group consisting of polysaccharides, glycerol esters, cellulose ethers, sorbitan esters, polysorbates and any combination thereof.

30 29. The stable controlled release coating composition of claim 28 wherein said polysorbate is polyoxyethylene sorbitan mono-oleate.

2003211146 04 Jul 2007

PROPERDATA03211146 amendments doc-27762507

30. The stable controlled release coating composition of claim 29 wherein said polyoxyethylene sorbitan mono-oleate is present in an amount of up to about 0.5% by weight of the coat composition.

5 31. The stable controlled release coating composition of claim 30 wherein said polyoxyethylene sorbitan mono-oleate is present in an amount of from about 0.1% to about 0.3% by weight of the coat composition.

10 32. The stable controlled release coating composition of any one of claims 14 to 31 wherein said colorant is selected from group consisting of iron oxide pigments, titanium dioxide, aluminum Lakes and any combination thereof.

15 33. The stable controlled release coating composition of claim 32 wherein said colorant is titanium dioxide.

34. The stable controlled release coating composition of any one of claims 14 to 33 wherein said colorant is present in an amount of from about 0.1% to about 10% by weight of the coat composition.

20 35. The stable controlled release coating composition of claim 34 wherein said colorant is present in an amount of from about 0.1% to about 5% by weight of the coat composition.

25 36. The stable controlled release coating composition of claim 35 wherein said colorant is present in an amount of from about 0.1% to about 2% by weight of the coat composition.

30 37. The stable controlled release coating composition of any one of claims 1 to 36 wherein said pharmaceutical oral dosage form is selected from the group consisting of tablets and capsules.

38. A stable controlled release monolithic coating composition for use in coating

2003211146 04 Jul 2007

PROPERO/H20211146 amendment doc-276520x7

a pharmaceutical oral dosage form, said coating comprising an aqueous dispersion of Eudragit NE30D, polyethylene glycol 8000, hydroxypropyl methylcellulose, talc, simethicone, titanium dioxide, and polyoxyethylene sorbitan mono-oleate, said Eudragit NE30D is present in an amount of from about 1% to 5 about 35% by weight of the coat composition, said polyethylene glycol is present in an amount of from about 0.1% to about 3% by weight of the coat composition, said hydroxypropyl methylcellulose is present in an amount of from about 0.1% to about 6% by weight of the coat composition, said talc is present in an amount of from about 0.1% to about 7% by weight of the coat composition, said simethicone 10 is present in an amount up to about 0.5% by weight of the coat composition, said polyoxyethylene sorbitan mono-oleate is present in an amount of up to about 0.5% by weight of the coat composition, said titanium dioxide is present in an amount of from about 0.1% to about 2% by weight of the coat composition; and composition is coated onto said pharmaceutical oral dosage form and cured at a temperature 15 at least equal to or greater than the melting point of said polyglycol.

39. The controlled release oral dosage form of claim 38, wherein said pharmaceutical dosage form is selected from the group consisting of tablets and capsules.

20

40. A controlled release oral dosage form comprising:

- a) a core, wherein said core comprises:
    - i) an effective amount of at least one therapeutically active agent, and
    - ii) one or more first pharmaceutically acceptable excipients, and
  - 25 b) a stable controlled release monolithic coating composition for coating said core, said coating composition comprising:
    - i) an aqueous dispersion of a neutral ester copolymer without any functional groups;
    - ii) a poly glycol having a melting point greater than 55°C, and
    - 30 iii) one or more second pharmaceutically acceptable excipients;
- wherein said coating composition is coated onto said core and cured at a

- 43 -

2003211146 04 Jul 2007

P:\OPERA\DATA\2003\1146\amendments.doc-27\16\2007

temperature at least equal to or greater than the melting point of the poly glycol.

41. A stable controlled release coating composition according to claim 1 or claim 38 substantially as hereinbefore described with reference to any one of the 5 examples.

42. A controlled release oral dosage form according to claim 40 substantially as hereinbefore described with reference to any one of the examples.

10

- 44 -